Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms (FODMAPendo)

Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms: a Randomized Controlled Trial

The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. bloating, nausea, constipation, diarrhoea and vomiting) attributable to irritable bowel syndrome, compared with a control group

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity, mostly, though not exclusively, in the pelvis. It is a chronic, estrogen-dependent inflammatory condition in which ectopic foci grow and proliferate under the action of estradiol, which plays a pro-inflammatory and anti-apoptotic role.

Pelvic pain represents the most typical manifestation of endometriosis. In particular, dysmenorrhea is the most frequent symptom.

In addition to typical gynecological symptoms, gastrointestinal symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) affect up to 90 percent of patients with endometriosis It has been reported how a diet low in oligosaccharides, disaccharides, monosaccharides, and fermentable polyols (FODMAP diet) is superior to other dietary treatments for the treatment of symptoms associated with irritable bowel syndrome.

Short-chain polysaccharides (FODMAPs) are found in a variety of fruits, vegetables and grains. FODMAPs are poorly absorbed in the gut, and are readily fermented by bacteria.

Their osmotic actions and gas production cause distention of the intestinal lumen inducing pain and bloating in patients with visceral hypersensitivity, with secondary effects on intestinal motility.

Although hormonal therapies represent the therapeutic cornerstone of endometriosis, we hypothesize that the FODMAP diet may represent a complementary and adjuvant approach for the treatment of abdominal/pelvic algic symptoms (and particularly bowel-type symptoms), resulting in significant improvement in the quality of life of affected women.

The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can improve algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome,

Eligible women will be selected among those attending the Endometriosis Clinic of the "L. Mangiagalli ", IRCCS Ca 'Granda Foundation and Ospedale Maggiore Policlinico, and will be randomized into two homogeneous groups ("intervention" and "control") (1:1): the intervention group will consist of women with symptomatic endometriosis and concomitant bowel symptoms under estro-progestin or progestin treatment, who will be asked to follow a dietary regimen based on the principles of the FODMAP diet; women in the control group will not be given specific instructions about the diet to follow.

Women will be randomized and assigned to two groups: 1) "FODMAP diet" (FD) group; 2) "usual diet" (UD) group. All patients participating in the study will undergo clinical and ultrasonographic evaluation at the beginning of the study, after 3 months and after 6 months. On these occasions, women will be routinely asked to complete some questionnaires, one on pain (a numerical rating scale, NRS), to the evaluation of gastrointestinal symptoms (NRS related to intestinal symptoms, such as abdominal bloating, nausea, constipation, diarrhea and vomiting), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the Hospital Anxiety and Depression scale, HADS), one on sexual functioning (theFemale Sexual Function Index, FSFI) and one on the global impression of change (Patients' Global Impression of Change scale, PGIC). Women will also be asked to rate the degree of satisfaction with their treatment.

Patients randomized into the intervention group will participate in an initial meeting with the dietitian during which they will receive targeted nutritional counseling. They will be provided with the dietary pattern to follow. Follow-up of the diet will include telephone follow-up 6 to 8 weeks after the start of the study, at 3 months and at 6 months to assess dietary adherence.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

150

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Milan, Italia, 20122
        • Reclutamiento
        • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
        • Contacto:
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Age between 18 and 45 years
  • BMI between 18.5 and 24.9,
  • Surgical, clinical or instrumental diagnosis of endometriosis
  • Presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, on estro-progestin or progestin treatment or in the absence of hormonal treatment

Exclusion Criteria:

  • Associated conditions that may cause pelvic pain independent of the presence of endometriosis (e.g., pelvic varices and salpingitis outcomes)
  • chronic inflammatory bowel disease (Crohn's disease or ulcerative rectocolitis).
  • patients with obstructive uropathy, subocclusive intestinal stenosis
  • complex adnexal masses or typical endometriomas greater than 5 cm in diameter.
  • women who are obese (BMI ≥ 30) or underweight (BMI < 18)
  • women on vegetarian-vegan dietary regimens,
  • women with metabolic diseases that require specific dietary indications such as in the case of diabetes and celiac disease.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: FODMAP diet group
Patients randomized to the treatment arm were proposed to follow a FODMAP diet throughout the study period
Diet low in oligosaccharides, disaccharides, monosaccharides and fermentable polyols
Sin intervención: Usual diet group

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change of pain related syntomps in patients with bowel symptoms
Periodo de tiempo: 6 months
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can change algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, compared with a control group. The outcome will be measured trough Numerical Rating Scale (NRS) on dismenorrea, dyspareunia, non menstrual pelvic pain and dyschezia.
6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gastrointestinal syntomps, patient satisfaction, health-related quality of life, psychological conditions, patient's overall condition and anthropometric parameters
Periodo de tiempo: 6 months
  1. Assessment of patient satisfaction during treatment, measured using a five-point Likert scale
  2. Assessment of gastrointestinal symptoms (abdominal bloating, nausea, constipation, diarrhea, and vomiting) using a numerical rating scale (NRS, 0 to 10)
  3. The impact on health-related quality of life assessed using the Short-Form Health Survey 12 (SF-12)
  4. The impact on sexual function using the Female Sexual Function Index (FSFI) questionnaire
  5. The impact on patients' psychological conditions using the HADS (Hospital Anxiety and Depression Scale)
  6. The patient's overall condition using the Patients' Global Impression of Change (PGIC) scale, a seven-point scale (greatly improved, much improved, slightly improved, unchanged, slightly worsened, muc
  7. Changes in anthropometric parameters through changes in BMI and impedance analysis of body composition
6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de marzo de 2024

Finalización primaria (Estimado)

15 de noviembre de 2026

Finalización del estudio (Estimado)

15 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

10 de mayo de 2024

Primero enviado que cumplió con los criterios de control de calidad

12 de mayo de 2026

Publicado por primera vez (Actual)

15 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de mayo de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir